Lupus最新文献

{"title":"Reversible dilated cardiomyopathy in systemic lupus erythematosus: A case report.","authors":"Jorge Reis, Marta Leite, Guilherme Jesus, Diogo Ferreira, Sofia Pereira, Andreia Seixas","doi":"10.1177/09612033251337516","DOIUrl":"10.1177/09612033251337516","url":null,"abstract":"<p><p>A 40-year-old woman presented with new-onset heart failure with reduced ejection fraction (HFrEF) accompanied with systemic symptoms, including arthralgia, cutaneous lesions, and Raynaud's phenomenon. Initial investigation led to the diagnosis of systemic lupus erythematosus (SLE), with subsequent finding of dilated cardiomyopathy, a rare but severe secondary manifestation of SLE. Early recognition and appropriate management of underlying autoimmune conditions can lead to substantial improvement in cardiac function, emphasizing the need for comprehensive evaluation in patients with <i>de novo</i> heart failure and systemic symptoms.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"757-760"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infection vulnerability in pregnant women with and without systemic lupus erythematosus.","authors":"Hiba I Khogali, Aaesha M Alhebsi, Meera A Altamimi, Ghada Sm Al-Bluwi, Virgie Guy Pedo, Ali M Al Dhanhani","doi":"10.1177/09612033251344195","DOIUrl":"10.1177/09612033251344195","url":null,"abstract":"<p><p>ObjectiveSystemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that predominantly affects females. SLE poses risks to the mother and fetus during pregnancy. Information on infection rates during pregnancy in patients with SLE is scarce. Therefore, this study assessed infection risk during pregnancy in women with and without SLE, and identified the factors influencing susceptibility to infections.MethodsWe conducted a retrospective cohort analysis using medical records from Tawam Hospital, Abu Dhabi, United Arab Emirates. Emirati women diagnosed with SLE who experienced one or more pregnancies between January 2010 and August 2023 were included in the study. Patients with SLE were compared with an age-matched control group of women without SLE. The control group was systematically selected from the hospital records of the same period. Demographic details, clinical data, and comprehensive infection histories during and before pregnancy were examined. Univariate and multivariate regression analyses were used to identify the factors contributing to the risk of infection in pregnant women with SLE.ResultsData from 87 pregnancies in 41 women with SLE were analyzed. The mean age at conception was higher in women with SLE compared to the control group. The rates of infections (54.7% vs 29.8%), adverse fetal outcomes (48.3% vs 24.2%), and maternal outcomes (71.3% vs 43%) were significantly higher in the SLE group than in the control group. Respiratory infections were the most prevalent infection type. No variable was found to increase the risk of infection; however, hydroxychloroquine use during pregnancy was significantly associated with a reduced risk of infection.ConclusionsThe risks of infection and adverse outcomes are significantly higher in pregnant women with SLE than in the non-SLE population. Hydroxychloroquine use during pregnancy was crucial in reducing infection risk. These findings underscore the need for targeted interventions and a multidisciplinary care approach to improve pregnancy outcomes in women with SLE.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"705-712"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of myocardial dysfunction of patients with systemic lupus erythematosus based on myocardial perfusion imaging and analysis of potential influencing factors.","authors":"Kejing Shao, Fenghong Yuan, Fei Chen, Wei Hu, Bao Zhu","doi":"10.1177/09612033251335808","DOIUrl":"10.1177/09612033251335808","url":null,"abstract":"<p><p>The incidence and prevalence of systemic lupus erythematosus (SLE) have increased annually over the past decade. The involvement of myocardium is one of the main reasons for the poor prognosis of patients with SLE. Identifying myocardial involvement in patients with autoimmune diseases and providing early targeted treatment can improve patient outcomes. The aim of this study is to evaluate myocardial dysfunction in patients with SLE using ^99mTc-MIBI rest gated myocardial perfusion imaging (rGMPI) and to investigate factors associated with myocardial dysfunction. 76 patients with SLE were prospectively enrolled in the study and 46 patients without autoimmune diseases or other inflammatory diseases who had undergone ^99mTc-MIBI rGMPI were selected as a control group. Results of relevant blood test indicators, echocardiography and rGMPI were recorded, and comparison was made between the two groups. Meanwhile, based on diagnostic results of rGMPI, SLE patients were divided into myocardial dysfunction group and normal myocardial function group and to analyze the influencing factors of myocardial dysfunction in SLE patients. The incidence of myocardial dysfunction was significantly higher in SLE patients than in controls (30.3% vs 0%, 2= 16.131, <i>p</i> < .001). Moderate/severe disease activity, decreased myocardial perfusion and positive anti-SSA/Ro52kDa antibody were associated with impaired myocardial function in SLE patients (OR = 2.753, 5.359, 3.646; <i>p</i> = .049, 0.015, 0.014). Positive anti-SSA/Ro52kDa antibody was is independently correlated with myocardial dysfunction in SLE patients [OR (95% CI) = 3.159 (1.071-9.316), <i>p</i> = .037]. In conclusion, ^99mTc-MIBI rGMPI can noninvasively evaluate myocardial dysfunction in patients with SLE and provide evidence for clinical treatment decisions. Positive anti-SSA/Ro52kDa antibody was an independent risk factor for myocardial dysfunction in SLE patients.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"679-686"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subclinical atherosclerosis is associated with future cardiovascular events in lupus patients at apparent low cardiovascular risk.","authors":"Arthur Mageau, Florence Arnoult, Marie-Paule Chauveheid, Thomas Papo, Karim Sacre","doi":"10.1177/09612033251344200","DOIUrl":"10.1177/09612033251344200","url":null,"abstract":"<p><p>ObjectivesPrediction models based on traditional risk factors underestimate the risk for cardiovascular events (CVE) in SLE. We aimed to assess the occurrence of CVE in SLE patients according to their baseline subclinical atherosclerosis status.MethodsCarotid intima-media thickness at the carotid bulb level (CIMT) was prospectively assessed in consecutive SLE patients followed in our national reference center for rare diseases by a single evaluator, between February 2012 and February 2013. SLE patients with known CVE were excluded. CIMT >1.5 mm defined carotid plaque as a measure of subclinical atherosclerosis. The main outcome was a CVE defined as the occurrence during follow-up of myocardial infarction, ischemic stroke or symptomatic peripheral arterial disease.Results63 SLE patients (82.5% female, median age 39 [32-44.5]) were included. Among them, 24 (38.1%) had a carotid plaque >1.5 mm at baseline and 7 (11.1%) experienced a cardiovascular event during a median follow-up of 10.7 [8.2-11.0] years. All CVE occurred in the group of patients who had a carotid plaque at baseline. In the multivariable analysis, we observed that, after adjusting for the Framingham score and the body mass index, the presence of a carotid plaque was significantly associated with the occurrence of a cardiovascular event: odds ratio [95% confidence interval] = 17.2 ; 95 CI: [1.15-2499]; <i>p</i> = 0.039).ConclusionSubclinical atherosclerosis defined as a carotid plaque >1.5 mm is significantly associated with the clinical cardiovascular risk in SLE. Subclinical atherosclerosis should be regularly assessed in this population as part of the global cardiovascular risk evaluation.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"751-756"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis.","authors":"Susan Manzi, Jorge Sánchez-Guerrero, Naoto Yokogawa, Joerg Wenzel, Josephine C Ocran-Appiah, Julia Hn Harris, Munther Khamashta, Bernard Rubin, Norma Lynn Fox, Roger A Levy, Victoria P Werth","doi":"10.1177/09612033251337130","DOIUrl":"10.1177/09612033251337130","url":null,"abstract":"<p><p>ObjectiveTo investigate the effects of belimumab (BEL) on systemic lupus erythematosus (SLE) mucocutaneous and vasculitis manifestations.MethodsThis post hoc, integrated Belimumab Summary of Lupus Efficacy (Be-SLE) analysis pooled data from five international Phase 3, randomized, placebo (PBO)-controlled BEL trials (BLISS-52 [NCT00424476; conducted in 2007-2009], BLISS-76 [NCT00410384; 2007-2009], BLISS-SC [NCT01484496; 2011-2015], North East Asia [NCT01345253; 2011-2015], EMBRACE [NCT01632241; 2013-2018]). Adults with active SLE and Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) score ≥6 (BLISS-52, BLISS-76) or ≥8 (BLISS-SC, North East Asia, EMBRACE), randomized to BEL (10 mg/kg/month intravenously or 200 mg/week subcutaneously) or PBO, plus standard therapy (ST) were included. Mucocutaneous and vasculitis manifestations (listed below) were measured (baseline and every 4 weeks) for 52 weeks using SELENA-SLEDAI and British Isles Lupus Assessment Group (BILAG).ResultsOf 3086 patients (BEL, <i>n</i> = 1869; PBO, <i>n</i> = 1217), 85% (BEL and PBO) by SELENA-SLEDAI and 58% (BEL) and 62% (PBO) by BILAG (moderate or severe activity) had mucocutaneous manifestations, and <10% had vasculitis at baseline. At Week 52, significantly more BEL-treated than PBO-treated patients demonstrated improvements in SELENA-SLEDAI (59% vs 49%; <i>p</i> < .0001) and BILAG (54% vs 43%; <i>p</i> < .0001) mucocutaneous domains. Significant differences between-treatment favored BEL at Week 52 for resolution of all SELENA-SLEDAI items (vasculitis, rash, alopecia, and mucosal ulcers), and nine of 20 BILAG items (mild maculopapular eruption, localized active discoid lesions, mild alopecia, small mucosal ulceration, malar erythema, subcutaneous nodules, swollen fingers, major cutaneous vasculitis including ulcers, and minor cutaneous vasculitis).ConclusionPatients with SLE treated with BEL plus ST experienced significant improvements in most mucocutaneous and vasculitis manifestations compared with patients receiving PBO plus ST. These data provide additional support for the use of BEL in SLE and show that it is associated with skin improvements.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"666-678"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombocytopenia and autoimmune hemolytic anemia in antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid syndrome alliance for clinical trials and InternatiOnal networking (APS ACTION) clinical database and repository (\"Registry\").","authors":"Zeynep Belce Erton, Rebecca K Leaf, Danieli de Andrade, Ann Clarke, Maria G Tektonidou, Vittorio Pengo, Savino Sciascia, Jose Pardos-Gea, Nina Kello, Diana Paredes-Ruiz, Chary Lopez-Pedrera, H Michael Belmont, Paul R Fortin, Guilherme Ramires de Jesús, Tatsuya Atsumi, Zhouli Zhang, Maria Efthymiou, D Ware Branch, Giulia Pazzola, Laura Andreoli, Alí Duarte-García, Esther Rodriguez-Almaraz, Michelle Petri, Ricard Cervera, Bahar Artim-Esen, Rosana Quintana, Hui Shi, Yu Zuo, Rohan Willis, Megan R W Barber, Leslie Skeith, Massimo Radin, PierLuigi Meroni, Maria Laura Bertolaccini, Hannah Cohen, Robert Roubey, Doruk Erkan","doi":"10.1177/09612033251332258","DOIUrl":"10.1177/09612033251332258","url":null,"abstract":"<p><p>Background/PurposeAPS ACTION Registry was created to study the natural course of antiphospholipid syndrome (APS) over 10 years in persistently antiphospholipid antibody (aPL) positive patients with or without systemic autoimmune rheumatic diseases (SARDs). Our primary objective was to compare the characteristics of aPL-positive patients with or without thrombocytopenia (TP) and/or autoimmune hemolytic anemia (AIHA).MethodsThe registry inclusion criteria are positive aPL based on the Revised Sapporo APS Classification Criteria, tested at least twice within 1 year prior to enrollment. For the primary comparison of demographic, clinical, and serologic characteristics in this retrospective study, we divided patients into two groups: TP/AIHA ever and never. Thrombocytopenia was defined as a platelet count of <100,000 x 10⁹/L tested twice at least 12 weeks apart, and AIHA was defined as anemia with hemolysis and a positive direct antiglobulin test (DAT). For the secondary analysis, we compared patients with TP versus AIHA, and the immunosuppressive use stratified by systemic lupus erythematosus (SLE) classification.ResultsAs of April 2022, of 1,039 patients (primary aPL/APS: 618 [59%]; SLE classification: 334 [31%]) included in the registry, 228 (22%) had baseline (historical or current) TP and/or AIHA (TP only: 176 [17%]; AIHA only: 35 [3%], and both: 17 [2%]). Thrombocytopenia and/or AIHA was significantly associated with Asian race, SLE classification, cardiac valve disease, catastrophic/microvascular APS, triple aPL (lupus anticoagulant, anticardiolipin antibody, and anti-β₂-glycoprotein-I antibody) positivity, and SLE-related serologic and inflammatory markers. When 101/618 (16%) primary aPL/APS patients and 101/334 (34%) SLE patients with TP and/or AIHA were compared, azathioprine and mycophenolate mofetil were more commonly reported in lupus patients, however corticosteroid, intravenous immunoglobulin, and rituximab use were similar between groups.ConclusionIn our large multi-center international cohort of persistently aPL-positive patients, approximately one-fifth had active or historical TP and/or AIHA at registry entry; half of these patients had additional SLE. Cardiac valve disease, catastrophic/microvascular APS, and triple aPL-positivity were aPL-related clinical and laboratory manifestations associated with TP and/or AIHA, suggesting a more severe APS clinical phenotype in aPL-patients with TP and/or AIHA.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"617-625"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical significance of anti-Ro and Anti-La antibodies: The role of isolated anti-La.","authors":"Clara Sangüesa, Alejandro Olivé, Iñigo Rúa-Figueroa, Irene Altabás González, Julia Martinez-Barrio, María Galindo-Izquierdo, Jaime Calvo Alén, Esther Uriarte Isacelaya, Eva Tomero Muriel, Mercedes Freire González, Víctor Martínez-Taboada, Eva Salgado-Pérez, Paloma Vela, Antonio Fernández-Nebro, Javier Narváez, Raúl Menor Almagro, Gregorio Santos Soler, Javier Novoa, Ángela Pecondón, Elena Aurrecoechea Aguinaga, Oihane Ibarguengoitia, Carlos Montilla Morales, Gema Bonilla Hernán, Vicente Torrente-Segarra, Tarek Carlos Salman Monte, Mónica Ibáñez Barceló, María Jesús García-Villanueva, Rocío Caño Alameda, Joan Calvet Fontonova, Tomás Ramón Vázquez Rodríguez, Víctor Quevedo Vila, Lorena Expósito, Virginia Moreira, José Luis Andréu Sánchez, Beatriz Paredes Romero, Clara Moriano Morales, Loreto Horcada, Nuria Lozano-Rivas, Ana Pérez Gómez, José María Pego-Reigosa","doi":"10.1177/09612033251331249","DOIUrl":"10.1177/09612033251331249","url":null,"abstract":"<p><p>ObjectivesThe aim of the present study was to describe demographic, clinical, and immunological characteristics of SLE patients with anti-La/SSB antibodies positive versus anti-La/SSB negative patients.MethodsRetrospective cross-sectional study, including all patients with SLE (≥4 ACR-1997 criteria) recruited in RELESSER registry. Sociodemographic, clinical, serological and comorbidities variables were collected. Anti-Ro-/La + patients were compared with the rest of the patients.ResultsIn a study involving 4219 systemic lupus erythematosus (SLE) patients, 44/3893 (1.1%) were found to be positive for isolated anti-La/SSB antibodies. The mean age was 33.77 years, with a majority being female (88.6%) and Caucasian (90.5%). The most frequent comorbidities were smoking (48.8%), dyslipidemia (47.7%), and arterial hypertension (31.8%). Photosensitivity and mucosal ulcers were more common in anti-Ro+/La + patients compared to anti-Ro+/La- and anti-Ro-/La- patients. Anti-Ro+/La + patients had a lower frequency of lupus nephritis compared to anti-Ro+/La- patients. A multivariable regression model, considering various confounding factors, was applied to compare anti-La/SSB positive patients with negative ones. Isolated anti-La/SSB positive patients showed a lower occurrence of lupus nephritis and a higher frequency of cardiac manifestations.ConclusionsThe study suggests that patients with isolated anti-La/SSB antibodies may have a unique clinical profile, with a potential protective effect against lupus nephritis but an increased likelihood of cardiac manifestations.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"571-578"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone marrow MxA staining reflects anifrolumab response in formerly treatment-refractory systemic lupus erythematosus with initial pancytopenia.","authors":"Claus-Juergen Bauer, Joerg Wenzel, Valentin Sebastian Schäfer","doi":"10.1177/09612033251330090","DOIUrl":"10.1177/09612033251330090","url":null,"abstract":"","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"648-650"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progenitor cells and circulating endothelial cells are associated with disease activity and damage in systemic lupus erythematosus patients.","authors":"Gonzalo Silveira, Sabrina Ranero, Adriana Carlomagno, Andreina Brugnini, Natalia Trias, Daniela Lens, Martín Rebella, Álvaro Danza, Sofía Grille","doi":"10.1177/09612033251330124","DOIUrl":"10.1177/09612033251330124","url":null,"abstract":"<p><p>BackgroundDespite advancements in treatment, patients with Systemic Lupus Erythematosus (SLE) frequently experience disease flares, which contribute to organ damage and increase the risk of premature death. Assessing disease activity is essential for optimizing treatment and preventing further organ damage. This study aimed to investigate the relationship between levels of progenitor and circulating endothelial cells and SLE disease activity, as well as accumulated organ damage.MethodsWe conducted a case-control study measuring levels of CD34+CD45low/- progenitor cells, CD34+CD45low/-CD133+ progenitor cells, Endothelial Progenitor Cells (EPC), and Circulating Endothelial Cells (CEC) in peripheral blood using flow cytometry.ResultsThe study included 32 SLE patients and 28 matched controls. SLE patients exhibited significantly lower levels of CD34+CD45low/- progenitor cells (<i>p</i> = .001), CD34+CD45low/-CD133+ progenitor cells (<i>p</i> = .016), EPC (<i>p</i> = .018), and CEC (<i>p</i> < .001) compared to controls. Additionally, the cell subpopulations correlated with SLE activity biomarkers, with CD34+CD45low/- progenitor cells showing a moderate negative correlation with C3 and C4 levels. Notably, patients with an SDI score ≥1 had significantly higher levels of CD34+CD45low/- progenitor cells, CD34+CD45low/- CD133+ progenitor cells, EPC, and CEC compared to those without organ damage (<i>p</i> = .0073, <i>p</i> = .018, <i>p</i> = .018, and <i>p</i> = .020, respectively).ConclusionOur findings reveal that CD34+CD45low/- progenitor cells, CD34+CD45low/-CD133+ progenitor cells, EPC, and CEC are significantly reduced in SLE patients and are associated with disease activity and organ damage. These results suggest that CD34+CD45low/- progenitor cells, in particular, could serve as potential biomarkers for monitoring disease activity and organ damage in SLE patients. Prospective studies are warranted to confirm these findings.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"551-561"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reversible lymphoproliferative disorder in systemic lupus erythematosus treated with mycophenolate mofetil: A case report and literature review.","authors":"Hiroto Tomoda, Muneo Nakaya, Seiichiro Nakabeppu, Hiroaki Miyoshi, Koichi Ohshima, Yuji Miyoshi","doi":"10.1177/09612033251330101","DOIUrl":"10.1177/09612033251330101","url":null,"abstract":"<p><p>BackgroundMycophenolate mofetil (MMF) is widely used to treat systemic lupus erythematosus (SLE), particularly in cases with severe and organ-threatening complications such as lupus nephritis. However, multiple reports have documented lymphoproliferative disorder (LPD) in patients with SLE undergoing MMF therapy, predominantly developing in the central nervous system and requiring aggressive treatment, including chemotherapy, radiation, and surgery.Case ReportWe herein report the case of a 58-year-old female patient with SLE who developed cervical, hepatic hilar, and para-aortic lymphadenopathy 8 years after initiating MMF treatment. Histopathological examination of the left cervical lymph node revealed features consistent with polymorphic LPD. MMF was discontinued, and after 2 months of surveillance, the enlarged lymph nodes regressed without need for additional treatment.ConclusionTo the best of our knowledge, this is the first reported case of MMF-associated LPD occurring outside the central nervous system in a patient with SLE, which resolved spontaneously upon MMF withdrawal. Clinicians should remain vigilant regarding the possibility of MMF-associated LPD when administering MMF to patients with SLE.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"633-639"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}